Impact of Recombinant Replacement Therapy Detailed in Genetic Clotting Disorder

(MedPage Today) -- A recombinant replacement for the ADAMTS13 protein (Adzynma) missing in congenital thrombotic thrombocytopenic purpura (TTP) restored levels and reduced acute TTP events, according to interim trial data that led to FDA approval...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news